BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

685 related articles for article (PubMed ID: 30405135)

  • 1. Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer.
    Niemeijer AN; Leung D; Huisman MC; Bahce I; Hoekstra OS; van Dongen GAMS; Boellaard R; Du S; Hayes W; Smith R; Windhorst AD; Hendrikse NH; Poot A; Vugts DJ; Thunnissen E; Morin P; Lipovsek D; Donnelly DJ; Bonacorsi SJ; Velasquez LM; de Gruijl TD; Smit EF; de Langen AJ
    Nat Commun; 2018 Nov; 9(1):4664. PubMed ID: 30405135
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PD-L1 PET/CT Imaging with Radiolabeled Durvalumab in Patients with Advanced-Stage Non-Small Cell Lung Cancer.
    Smit J; Borm FJ; Niemeijer AN; Huisman MC; Hoekstra OS; Boellaard R; Oprea-Lager DE; Vugts DJ; van Dongen GAMS; de Wit-van der Veen BJ; Thunnissen E; Smit EF; de Langen AJ
    J Nucl Med; 2022 May; 63(5):686-693. PubMed ID: 34385342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantification of PD-L1 Expression with
    Huisman MC; Niemeijer AN; Windhorst AD; Schuit RC; Leung D; Hayes W; Poot A; Bahce I; Radonic T; Oprea-Lager DE; Hoekstra OS; Thunnissen E; Hendrikse NH; Smit EF; de Langen AJ; Boellaard R
    J Nucl Med; 2020 Oct; 61(10):1455-1460. PubMed ID: 32060213
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical evaluation and pilot clinical study of [
    Ma X; Zhou X; Hu B; Li X; Yao M; Li L; Qin X; Li D; Yao Y; Hou X; Liu S; Chen Y; Wang Z; Zhou W; Li N; Zhu H; Jia B; Yang Z
    Eur J Nucl Med Mol Imaging; 2023 Nov; 50(13):3838-3850. PubMed ID: 37555904
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Study of
    Niemeijer AN; Oprea-Lager DE; Huisman MC; Hoekstra OS; Boellaard R; de Wit-van der Veen BJ; Bahce I; Vugts DJ; van Dongen GAMS; Thunnissen E; Smit EF; de Langen AJ
    J Nucl Med; 2022 Mar; 63(3):362-367. PubMed ID: 34272316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association Between PD-L1 Expression and Metabolic Activity on
    Takada K; Toyokawa G; Tagawa T; Kohashi K; Akamine T; Takamori S; Hirai F; Shoji F; Okamoto T; Oda Y; Maehara Y
    Anticancer Res; 2017 Dec; 37(12):7073-7082. PubMed ID: 29187498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early Phase I Study of a
    Xing Y; Chand G; Liu C; Cook GJR; O'Doherty J; Zhao L; Wong NCL; Meszaros LK; Ting HH; Zhao J
    J Nucl Med; 2019 Sep; 60(9):1213-1220. PubMed ID: 30796165
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FDG-PET in the evaluation of response to nivolumab in recurrent non-small-cell lung cancer.
    Higuchi M; Owada Y; Inoue T; Watanabe Y; Yamaura T; Fukuhara M; Hasegawa T; Suzuki H
    World J Surg Oncol; 2016 Sep; 14(1):238. PubMed ID: 27595749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Negative Correlation Between
    Wu L; Liu J; Wang S; Bai M; Wu M; Gao Z; Li J; Yu J; Liu J; Meng X
    Front Endocrinol (Lausanne); 2022; 13():913631. PubMed ID: 35846323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Significance of the PD-L1 Expression in Non-Small-Cell Lung Cancer: Trenchant Double Swords as Predictive and Prognostic Markers.
    Takada K; Toyokawa G; Shoji F; Okamoto T; Maehara Y
    Clin Lung Cancer; 2018 Mar; 19(2):120-129. PubMed ID: 29153898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First-in-Humans Evaluation of a PD-L1-Binding Peptide PET Radiotracer in Non-Small Cell Lung Cancer Patients.
    Zhou X; Jiang J; Yang X; Liu T; Ding J; Nimmagadda S; Pomper MG; Zhu H; Zhao J; Yang Z; Li N
    J Nucl Med; 2022 Apr; 63(4):536-542. PubMed ID: 34326125
    [No Abstract]   [Full Text] [Related]  

  • 12. A novel [
    Puyalto A; Rodríguez-Remírez M; López I; Iribarren F; Simón JA; Ecay M; Collantes M; Vilalta-Lacarra A; Francisco-Cruz A; Solórzano JL; Sandiego S; Peñuelas I; Calvo A; Ajona D; Gil-Bazo I
    Front Immunol; 2023; 14():1272570. PubMed ID: 37841258
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Positive Conversion of PD-L1 Expression After Treatments with Chemotherapy and Nivolumab.
    Haratake N; Toyokawa G; Tagawa T; Kozuma Y; Matsubara T; Takamori S; Akamine T; Yamada Y; Oda Y; Maehara Y
    Anticancer Res; 2017 Oct; 37(10):5713-5717. PubMed ID: 28982891
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Progress of PD-1/PD-L1 Inhibitors in Non-small Cell Lung Cancer].
    Jiang Z; Pan Z; Ren X
    Zhongguo Fei Ai Za Zhi; 2017 Feb; 20(2):138-142. PubMed ID: 28228226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of PD-L1 immunohistochemistry assays and response to PD-1/L1 inhibitors in advanced non-small-cell lung cancer in clinical practice.
    Villaruz LC; Ancevski Hunter K; Kurland BF; Abberbock S; Herbst C; Dacic S
    Histopathology; 2019 Jan; 74(2):269-275. PubMed ID: 30105871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In Vivo Imaging of the Programmed Death Ligand 1 by
    González Trotter DE; Meng X; McQuade P; Rubins D; Klimas M; Zeng Z; Connolly BM; Miller PJ; O'Malley SS; Lin SA; Getty KL; Fayadat-Dilman L; Liang L; Wahlberg E; Widmark O; Ekblad C; Frejd FY; Hostetler ED; Evelhoch JL
    J Nucl Med; 2017 Nov; 58(11):1852-1857. PubMed ID: 28588151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First exploration of the on-treatment changes in tumor and organ uptake of a radiolabeled anti PD-L1 antibody during chemoradiotherapy in patients with non-small cell lung cancer using whole body PET.
    Pouw JEE; Hashemi SMS; Huisman MC; Wijngaarden JE; Slebe M; Oprea-Lager DE; Zwezerijnen GJC; Vugts D; Ulas EB; de Gruijl TD; Radonic T; Senan S; Menke-van der Houven van Oordt CW; Bahce I
    J Immunother Cancer; 2024 Feb; 12(2):. PubMed ID: 38302416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of PD-1 on CD4+ T cells in peripheral blood associates with poor clinical outcome in non-small cell lung cancer.
    Zheng H; Liu X; Zhang J; Rice SJ; Wagman M; Kong Y; Zhu L; Zhu J; Joshi M; Belani CP
    Oncotarget; 2016 Aug; 7(35):56233-56240. PubMed ID: 27191652
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD147-mediated glucose metabolic regulation contributes to the predictive role of
    Li X; Fu Q; Zhu Y; Wang J; Liu J; Yu X; Xu W
    Mol Carcinog; 2019 Feb; 58(2):247-257. PubMed ID: 30320488
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Bensch F; van der Veen EL; Lub-de Hooge MN; Jorritsma-Smit A; Boellaard R; Kok IC; Oosting SF; Schröder CP; Hiltermann TJN; van der Wekken AJ; Groen HJM; Kwee TC; Elias SG; Gietema JA; Bohorquez SS; de Crespigny A; Williams SP; Mancao C; Brouwers AH; Fine BM; de Vries EGE
    Nat Med; 2018 Dec; 24(12):1852-1858. PubMed ID: 30478423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.